Thursday, July 9, 2026

biotech · Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma · CUE

Cue Biopharma

Cue Biopharma clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Boston, USA HQ
2014 Founded
37 Employees
Public company Type
CUE · NYSE Ticker
Company details
Status
Public
HQ
Boston, USA
Founded
2014
Employees
37
Programs
5
Drugs
0
Patents
30
Intelligence · Clinical Programs

Cue Biopharma projects

2 ClinicalTrials.gov programs sponsored by Cue Biopharma.

Cue Biopharma has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. CUE-101

    Cue Biopharma

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial
  2. CUE-101

    Cue Biopharma

    Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Cue Biopharma have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.